CYP19A1 and obesity disorder: Zhou et al administered GnRHa treatment combined with LNG-IUD or letrozole in 29 patients, 27 of whom achieved complete remission.9 Dong et al reported on three cases treated with GnRHa plus aromatase inhibitor in whom the disease remained stable for 2 years.22 In our previous study we used GnRHa combination therapy in 61 patients with obesity and 34 patients with recurrence, and achieved a high regression rate in these patients.23 24